— Know what they know.
Not Investment Advice

ENDV OTC

Endonovo Therapeutics, Inc.
1W: +0.0% 1M: -50.0% 3M: -50.0% YTD: -50.0% 1Y: -50.0% 3Y: -99.6% 5Y: -99.8%
$0.00
+0.00 (+0.00%)
 
OTC · Healthcare · Biotechnology · Tech Score Neutral · Power 47 · $15938 mcap · 240M float · 0.218% daily turnover · Short 100% of daily vol

Balance Sheet Trends

Total Assets
$19K +0.1% ▲
5Y CAGR: -62.5%
Total Liabilities
$29M +7.7% ▲
5Y CAGR: +11.2%
Shareholders Equity
-$29M -7.7% ▼
Cash & Investments
$12 +300.0% ▲
5Y CAGR: -75.4%
Total Debt
$7M +0.6% ▲
5Y CAGR: +0.8%
Net Debt
$7M +0.6% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$86K$98$2K$3$12
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$86K$98$2K$3$12
Net Receivables$944$0$0$0$0
Inventory$0$0$0$0$0
Other Current Assets$0$16K$18K$18K$18K
Total Current Assets$95K$16K$20K$18K$18K
Property, Plant & Equip.$0$0$0$0$0
Goodwill & Intangibles$2M$1M$619K$0$0
Long-Term Investments$2K$2K$2K$2K$2K
Other Non-Current Assets-$2K-$2K$0$0$0
Total Non-Current Assets$2M$1M$620K$2K$2K
Total Assets$2M$1M$640K$19K$19K
— Liabilities —
Accounts Payable$658K$882K$1M$3M$3M
Short-Term Debt$7M$7M$7M$7M$7M
Deferred Revenue$6M$0$0$0$0
Other Current Liabilities-$449K$17M$11M$12M$13M
Total Current Liabilities$18M$33M$25M$27M$29M
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$80K$80K$80K$80K$80K
Total Non-Current Liabilities$80K$80K$80K$80K$80K
Total Liabilities$18M$33M$25M$27M$29M
— Equity —
Common Stock$7K$21K$33K$54K$169K
Retained Earnings-$56M-$75M-$68M-$71M-$73M
Accumulated OCI-$2K-$2K-$33K$0$0
Total Stockholders Equity-$16M-$32M-$24M-$27M-$29M
Total Liabilities & Equity$2M$1M$640K$19K$19K
— Key Metrics —
Total Debt$7M$7M$7M$7M$7M
Net Debt$7M$7M$7M$7M$7M
Total Investments$2K$2K$2K$2K$2K

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms